Predict your next investment

Venture Capital
windhamventures.com

See what CB Insights has to offer

Investments

47

Portfolio Exits

6

Funds

2

About Windham Venture Partners

Windham Venture Partners is a Life Sciences technology commercialization firm. The firm builds and fosters start-up companies based on research-generated technologies that originate in top U.S. and global institutions. Windham Venture Partners also act as founder, investor and initial management for these companies. The firm's approach is focused on the earliest stages of the venture capital lifecycle: company formation and providing seed capital to initiate the technology commercialization process.

Windham Venture Partners Headquarter Location

1325 Avenue of the Americas 27th Floor

New York, New York, 10019,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Windham Venture Partners News

Delfi Diagnostics Raises $225M in Series B Financing

Jul 18, 2022

Delfi Diagnostics, Inc. , a Palo Alto, CA- and Baltimore, MD-based developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, raised USD225m in Series B funding. This round was led by DFJ Growth with participation from Eli Lilly and Company, Point72, Brown Advisory, Point Field Partners, Initiate Ventures, Open Field Capital, PTX Capital, and all existing investors including Cowen Healthcare Investments, Foresite Capital, Menlo Ventures, OrbiMed, funds and accounts advised by T. Rowe Price Associates, Inc., Northpond Ventures, Samsara BioCapital, Rock Springs Capital, AV8 Ventures, Illumina Ventures, Osage University Partners, and Windham Venture Partners. In conjunction with the funding, DFJ Growth Partner Justin Kao, joined Delfi’s board of directors. The company intends to use the funds for the continued development and commercialization of high-quality and accessible blood tests for single cancer early detection, multi-cancer early detection, and treatment monitoring. Led by Victor Velculescu, MD, PhD, CEO and Founder, Delfi has built a platform designed to efficiently develop high-quality liquid biopsy applications via a proprietary and scalable whole genome fragmentation approach. Delfi analyzes cell-free DNA fragments across the entire genome. This allows for a single, low-cost, and straightforward lab process for any test developed on the platform. When combined with breakthroughs in machine learning, the platform can deliver high-performing results for multiple applications. The company is currently validating the technology for early detection of lung and other cancers in a 15,000-person prospective trial called CASCADE-LUNG, and is working with multiple research institutions to develop additional applications including screening for other cancer types, multi-cancer early detection, and treatment monitoring. FinSMEs 18/07/2022

Windham Venture Partners Investments

47 Investments

Windham Venture Partners has made 47 investments. Their latest investment was in Delfi Diagnostics as part of their Series B on July 7, 2022.

CBI Logo

Windham Venture Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/18/2022

Series B

Delfi Diagnostics

$225M

No

4

11/4/2021

Series A - III

Valera Health

$15M

No

13

10/14/2021

Series A

Alto Neuroscience

$32M

Yes

8

9/22/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

7/20/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/18/2022

11/4/2021

10/14/2021

9/22/2021

7/20/2021

Round

Series B

Series A - III

Series A

Series B

Series C

Company

Delfi Diagnostics

Valera Health

Alto Neuroscience

Subscribe to see more

Subscribe to see more

Amount

$225M

$15M

$32M

$99M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

13

8

10

10

Windham Venture Partners Portfolio Exits

6 Portfolio Exits

Windham Venture Partners has 6 portfolio exits. Their latest portfolio exit was Personal Genome Diagnostics on December 23, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/23/2021

Acquired

$99M

12

8/11/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

6/30/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

8/27/2018

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

12/15/2017

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/23/2021

8/11/2021

6/30/2021

8/27/2018

12/15/2017

Exit

Acquired

Acquired

IPO

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

12

10

10

10

10

Windham Venture Partners Fund History

2 Fund Histories

Windham Venture Partners has 2 funds, including Windham Venture Partners I LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

1/31/2014

Windham Venture Partners I LP

Late-Stage Venture Capital

Closed

$20M

1

Windham Venture Partners II

Subscribe to see more

Subscribe to see more

10

Closing Date

1/31/2014

Fund

Windham Venture Partners I LP

Windham Venture Partners II

Fund Type

Late-Stage Venture Capital

Subscribe to see more

Status

Closed

Subscribe to see more

Amount

$20M

Sources

1

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.